Deccan Health Care Ltd Valuation Shifts to Very Attractive Amid Steep Price Decline

Valuation Metrics Signal Deep Discount

As of 24 Mar 2026, Deccan Health Care Ltd’s P/E ratio stands at 10.03, a notable contraction compared to its peers in the healthcare services sector. For context, Bliss GVS Pharma, a peer with a fair valuation, trades at a P/E of 18.58, while other companies such as Shukra Pharma and Kwality Pharma are priced at much higher multiples of 53.5 and 26.44 respectively. This stark difference highlights Deccan Health Care’s current undervaluation relative to sector standards.

Similarly, the company’s P/BV ratio is an exceptionally low 0.21, indicating the stock is trading at just over one-fifth of its book value. This is significantly below typical market norms and peer valuations, where companies often trade above book value, reflecting investor scepticism or concerns about asset quality and earnings sustainability.

Enterprise value multiples further reinforce this valuation gap. Deccan Health Care’s EV to EBITDA ratio is 4.75, markedly lower than peers such as Bliss GVS Pharma (13.56) and Shukra Pharma (43.86). The EV to EBIT ratio of 6.80 also suggests the market is pricing in subdued earnings expectations or operational challenges ahead.

Operational Performance and Returns

Despite the attractive valuation, the company’s return metrics remain subdued. The latest return on capital employed (ROCE) is a mere 2.02%, while return on equity (ROE) is even lower at 1.30%. These figures indicate limited profitability and efficiency in generating returns from capital invested, which likely contributes to the cautious market sentiment and depressed multiples.

Moreover, Deccan Health Care’s PEG ratio of 0.13 suggests the stock is undervalued relative to its earnings growth potential, although the low returns and micro-cap status add layers of risk for investors.

Price Performance and Market Context

The stock has endured a severe price correction over multiple time horizons. Year-to-date, the share price has declined by 37.88%, substantially underperforming the Sensex’s 14.70% gain over the same period. Over one year, the stock has lost 52.58%, while the benchmark index rose 5.47%. The five-year and three-year returns are deeply negative at -70.42% and -71.01% respectively, contrasting sharply with Sensex gains of 45.24% and 25.50% over those periods.

Today alone, the stock dropped 15.60%, hitting a low of ₹8.85, close to its 52-week low of ₹8.85 and far from its 52-week high of ₹24.40. This volatility and downward trend reflect ongoing investor concerns about the company’s growth prospects and financial health.

Comparative Valuation: Deccan Health Care vs Peers

When benchmarked against its healthcare services peers, Deccan Health Care’s valuation stands out as very attractive. While companies like Shukra Pharma and Jagsonpal Pharma are classified as very expensive with P/E ratios exceeding 28 and EV/EBITDA multiples above 19, Deccan Health Care’s multiples are less than half those levels. This divergence suggests the market is pricing in significant risk or underperformance for Deccan Health Care relative to its sector counterparts.

Other peers such as Lincoln Pharma and Venus Remedies trade at fair valuations with P/E ratios around 13.43 and 14.43 respectively, still well above Deccan Health Care’s 10.03. Even TTK Healthcare, rated attractive, trades at a P/E of 16.31, underscoring the deep discount currently afforded to Deccan Health Care.

Micro-Cap Status and Market Perception

Deccan Health Care’s micro-cap classification adds an additional layer of risk and volatility. Smaller market capitalisation stocks often face liquidity constraints and heightened sensitivity to market sentiment, which can exacerbate price swings. The company’s Mojo Score of 32.0 and a recent downgrade from Strong Sell to Sell on 23 Mar 2026 reflect cautious analyst sentiment, likely influenced by weak financial returns and operational challenges.

Investors should weigh the very attractive valuation against the company’s low profitability and historical underperformance. While the stock’s depressed multiples may offer a value entry point, the risks inherent in its micro-cap status and subdued returns cannot be overlooked.

Investment Outlook and Considerations

Deccan Health Care’s valuation metrics suggest the stock is trading at a significant discount to both its historical levels and peer group averages. The P/E ratio of 10.03 and P/BV of 0.21 are compelling from a pure valuation standpoint, especially when compared to sector averages that are often double or more. However, the company’s low ROCE and ROE, combined with its micro-cap status and recent share price volatility, warrant a cautious approach.

Investors seeking value in the healthcare services sector may find Deccan Health Care’s current price attractive, but should also consider the underlying operational challenges and market risks. The downgrade in Mojo Grade from Strong Sell to Sell indicates some improvement in outlook, yet the overall score of 32.0 remains weak, reflecting ongoing concerns.

In summary, while Deccan Health Care Ltd offers a very attractive valuation entry point, prospective investors must balance this against the company’s limited profitability, historical underperformance relative to the Sensex, and the inherent risks of a micro-cap stock in a competitive sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →